MSB 3.42% $1.21 mesoblast limited

My thoughts on what matters to MNK, page-12

  1. 5,491 Posts.
    lightbulb Created with Sketch. 8960
    I believe it is you who consistently reminds us that this forum is for discussion and sharing of differing opinions.

    So why do you seem so displeased if our opinions change over time or possibly offer a different perspective of what may have driven or will drive events?

    Why not discuss the topic at hand and the views currently expressed? Why do you feel the need to refer to past posts? It is neither helpful nor is it constructive to this discussion.

    And my reference to Michael's comments on MNK's need to diversify is in my opinion very relevant. As head of pharma partnering, he would have a seat at the table.

    And for Michael to say what he did speaks volumes, as it would be known to him that MNK would be listening in on his interview. So he would be careful not to misrepresent what MNK's position or intention are in terms of the partnership- in fact it would be very unwise of him to do so.
    Last edited by stockrock: 10/05/17
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.